Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Indaptus Therapeutics ( (INDP) ) has shared an update.
On June 25, 2025, Indaptus Therapeutics announced a one-for-twenty-eight reverse stock split of its common stock, effective after trading closed on June 26, 2025. This strategic move aims to increase the per share price and regain compliance with Nasdaq’s listing requirements, potentially strengthening the company’s investor base and market position.
The most recent analyst rating on (INDP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Underperform.
Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company’s valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Indaptus Therapeutics, Inc. is a clinical stage biotechnology company focused on developing innovative treatments for cancer and viral infections. The company is dedicated to pioneering new therapies and aims to enhance its market presence by making its stock more attractive to institutional investors.
Average Trading Volume: 6,385,971
Technical Sentiment Signal: Sell
Current Market Cap: $5.9M
See more insights into INDP stock on TipRanks’ Stock Analysis page.